These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38954991)

  • 1. Baricitinib as a treatment for myasthenia gravis: a case report.
    Iguchi M; Honjo J; Yamamoto T; Kanai K
    Neuromuscul Disord; 2024 Aug; 41():56-58. PubMed ID: 38954991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of alopecia areata-associated trachyonychia with baricitinib.
    Rózsa P; Degovics D; Baltás E; Gyulai R; Kemény L
    Int J Dermatol; 2024 Aug; 63(8):1089-1090. PubMed ID: 38514896
    [No Abstract]   [Full Text] [Related]  

  • 3. Oral Baricitinib Restores Hair Loss in Alopecia Areata.
    Slomski A
    JAMA; 2022 Jun; 327(24):2386. PubMed ID: 35762995
    [No Abstract]   [Full Text] [Related]  

  • 4. Two Phase 3 Trials of Baricitinib for Alopecia Areata.
    King B; Ohyama M; Kwon O; Zlotogorski A; Ko J; Mesinkovska NA; Hordinsky M; Dutronc Y; Wu WS; McCollam J; Chiasserini C; Yu G; Stanley S; Holzwarth K; DeLozier AM; Sinclair R;
    N Engl J Med; 2022 May; 386(18):1687-1699. PubMed ID: 35334197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baricitinib in Alopecia Areata.
    Messenger A; Harries M
    N Engl J Med; 2022 May; 386(18):1751-1752. PubMed ID: 35507486
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of moderate-to-severe alopecia areata in patients over the age of 65 years with baricitinib.
    Tang GT; Triwongwaranat D; Sinclair R; Joseph S; Eisman S; Rathnayake D; Varathan V; Trindade de Carvalho L; Bhoyrul B
    Clin Exp Dermatol; 2024 Jul; 49(8):875-878. PubMed ID: 38270233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Kupersmith MJ; Latkany R; Homel P
    Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring Janus kinase inhibitors for alopecia areata: a comprehensive review.
    Bushwereb R; Srivastava G
    Ital J Dermatol Venerol; 2024 Aug; 159(4):380-389. PubMed ID: 38780910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis.
    Guan R; Lin Y; Zhang C; Wang Z; Wu Z; Liu X; Chen X; Piao Y
    Arch Dermatol Res; 2024 Jul; 316(7):483. PubMed ID: 39042154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baricitinib: A Review in Severe Alopecia Areata.
    Fung S; Shirley M
    Am J Clin Dermatol; 2023 Jul; 24(4):661-668. PubMed ID: 37326792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
    Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
    Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myasthenia gravis with alopecia totalis.
    Noguchi Y; Fuchigami T; Morimoto S; Harada K
    Acta Paediatr Jpn; 1998 Feb; 40(1):99-101. PubMed ID: 9583214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
    King B; Ko J; Forman S; Ohyama M; Mesinkovska N; Yu G; McCollam J; Gamalo M; Janes J; Edson-Heredia E; Holzwarth K; Dutronc Y
    J Am Acad Dermatol; 2021 Oct; 85(4):847-853. PubMed ID: 34090959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus kinase inhibitors in the treatment of pyoderma gangrenosum: case report and review.
    Grisé A; Valere LC; Weinstein D; Sami N
    Arch Dermatol Res; 2024 May; 316(6):238. PubMed ID: 38795155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
    Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
    Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Janus kinase inhibitors: An innovative treatment for alopecia areata.
    Park H; Yu DA; Kwon O
    J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.
    Parra-Izquierdo I; Melrose AR; Pang J; Lakshmanan HHS; Reitsma SE; Vavilapalli SH; Larson MK; Shatzel JJ; McCarty OJT; Aslan JE
    Platelets; 2022 Apr; 33(3):404-415. PubMed ID: 34097573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
    Fitton J; Melville AR; Emery P; Nam JL; Buch MH
    Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.
    Senna M; Mostaghimi A; Ohyama M; Sinclair R; Dutronc Y; Wu WS; Yu G; Chiasserini C; Somani N; Holzwarth K; King B
    J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):583-593. PubMed ID: 38391212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.